WorldCat Identities

Ruoslahti, Erkki

Overview
Works: 22 works in 73 publications in 4 languages and 1,234 library holdings
Genres: Conference papers and proceedings  Laboratory manuals 
Roles: Editor, Author, Other
Publication Timeline
.
Most widely held works by Erkki Ruoslahti
Extracellular matrix components( Book )

11 editions published in 1994 in English and Polish and held by 599 WorldCat member libraries worldwide

The proliferation of extracellular matrix family members reflects the progress in cloning techniques in recent years. PCR, in particular, has made a tremendous difference. These technical advances are covered in this volume
Fibroblast surface protein( Book )

6 editions published in 1978 in English and held by 306 WorldCat member libraries worldwide

Immunoadsorbents in protein purification( Book )

11 editions published in 1976 in 3 languages and held by 177 WorldCat member libraries worldwide

Chemistry of tumor-associated antigens( Book )

4 editions published in 1978 in English and held by 104 WorldCat member libraries worldwide

Studies on the molecular basis of Gc polymorphism by Erkki Ruoslahti( )

4 editions published in 1966 in English and Swedish and held by 7 WorldCat member libraries worldwide

Targeting Breast Cancer Vasculature( Book )

6 editions published between 2003 and 2006 in English and held by 6 WorldCat member libraries worldwide

The main problems with current cancer therapies, including those for breast cancer, are that they are only partially effective and highly toxic. We work on a strategy that enhances the efficacy of anti-tumor therapies, while simultaneously decreasing the side effects. Our target is the vasculature of tumors. Tumor cells depend on blood supply and the tumor vasculature is accessible through the blood stream. An added advantage is that the vasculature is composed of normal cells, which are unlikely to develop resistance to treatments. We identify tumor-specific vascular markers by screening phage-displayed peptide libraries in mice bearing breast cancer xenografts or endogenous transgenic breast cancers. When the libraries are intravenously injected into the mice, the phage that have specific affinity for tumor vasculature home to the tumors. These peptides can then be used to carry drugs and other therapeutics into tumors. During the past year, we have identified (a) a tumor-homing peptide that binds to a collagen that is over-expressed in breast cancer vasculature and (b) peptides that home to lymphatic vessels in tumors. The homing peptides that target tumor lymphatics represent an important extension of the vascular targeting technology. Destroying the lymphatics and tumor cells in and around them with targeted drugs may be particularly useful in preventing metastasis
Immunoadsorbents in protein purification( Book )

1 edition published in 1976 in English and held by 5 WorldCat member libraries worldwide

Methods in enzymology( Book )

5 editions published between 1994 and 2005 in English and held by 5 WorldCat member libraries worldwide

Targeting Therapy Resistant Tumor Vessels( Book )

4 editions published between 2007 and 2008 in English and held by 4 WorldCat member libraries worldwide

Anti-angiogenic therapy appears to eliminate immature blood vessels. This paradoxically leads to improvement of tumor blood supply, as the structure and function of mature tumor blood vessels, not specific for anti-angiogenic effect, is normalized. This is a serious limitation to the anti-angiogenic therapy. The goal of this project is to specifically distinguish these "normalized" therapy resistant vessels in breast cancer from those sensitive to anti-angiogenic treatment. To achieve this, we have developed tumor models for vascular normalization and are using in vivo phage display and isolation of peptides that specifically home to normalized tumor vessels resistant to anti-angiogenic therapy. The results obtained in this study will enable specific targeting and thus treatment of breast cancer vessels not responding to standard anti-angiogenic therapy
New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer( Book )

4 editions published between 2001 and 2003 in English and held by 4 WorldCat member libraries worldwide

We have developed a novel substance, a polymeric form of fibronectin that we have named sFN, which has profound anti-tumor activities. Importantly, there seems to be no toxicity associated with systemic sFN treatment, even when given over several months. At least two characteristics of sFN contribute to its anti- tumor effects: it is both anti-angiogenic and anti-metastatic. sFN is a complex of fibronectin itself and a fragment from fibronectin, anastellin, which binds tightly to fibronectin and causes polymerization of fibronectin. We have now found that anastellin alone reproduces the anti-angiogenic effects of sFN and that plasma fibronectin is needed for anastellin to work in vivo. This is an important advance in understanding how anastellin (and other anti-angiogenic proteins) function. sFN is particularly effective in suppressing the growth and spreading of experimental ovarian cancer in mice. Anastellin, which would be easier to produce and administer may be a better compound to attempt to advance into clinical trials
Chemistry of tumor-associated antigens( Book )

2 editions published in 1978 in English and held by 3 WorldCat member libraries worldwide

Nanocrystal Targeting In Vivo( Book )

2 editions published in 2002 in English and held by 2 WorldCat member libraries worldwide

Inorganic nanostructures that interface with biological systems have recently attracted widespread interest in biology and medicine. Nanoparticles are thought to have potential as novel intravascular probes for both diagnostic (e.g., imaging) and therapeutic purposes (e.g., drug delivery). Critical issues for successful nanoparticle delivery include the ability to target specific tissues and cell types and escape from the biological particulate filter known as the reticuloendothelial system. We set out to explore the feasibility of in vivo targeting by using semiconductor quantum dots (qdots). Qdots are small (<10 nm) inorganic nanocrystals that possess unique luminescent properties; their fluorescence emission is stable and tuned by varying the particle size or composition. We show that ZnS-capped CdSe qdots coated with a lung-targeting peptide accumulate in the lungs of mice after i.v. injection, whereas two other peptides specifically direct qdots to blood vessels or lymphatic vessels in tumors. We also show that adding polyethylene glycol to the qdot coating prevents nonselective accumulation of qdots in reticuloendothelial tissues. These results encourage the construction of more complex nanostructures with capabilities such as disease sensing and drug delivery
Porous silicon–graphene oxide core–shell nanoparticles for targeted delivery of siRNA to the injured brain1( )

2 editions published in 2016 in English and held by 2 WorldCat member libraries worldwide

Abstract : A chemically targeted luminescent porous silicon–graphene oxide core–shell nanoparticle delivers siRNA for more effective gene silencing. Abstract : We report the synthesis, characterization, and assessment of a nanoparticle-based RNAi delivery platform that protects siRNA payloads against nuclease-induced degradation and efficiently delivers them to target cells. The nanocarrier is based on biodegradable mesoporous silicon nanoparticles (pSiNPs), where the voids of the nanoparticles are loaded with siRNA and the nanoparticles are encapsulated with graphene oxide nanosheets (GO–pSiNPs). The graphene oxide encapsulant delays release of the oligonucleotide payloads in vitro by a factor of 3. When conjugated to a targeting peptide derived from the rabies virus glycoprotein (RVG), the nanoparticles show 2-fold greater cellular uptake and gene silencing. Intravenous administration of the nanoparticles into brain-injured mice results in substantial accumulation specifically at the site of injury
Targeting Prostate Vasculture( Book )

2 editions published between 1999 and 2001 in English and held by 2 WorldCat member libraries worldwide

We proposed to identify peptides that home to the vasculature of prostate. Peptides capable of homing to the prostate vasculature may allow imaging of the prostate for diagnostic purposes. They will also make it possible to direct into the prostate treatments that can reduce the prostate's size and, therefore, reduce the risk of developing prostate cancer. Over the course of this grant, we identified a peptide that homes specifically to mouse prostate tissue (SMSIARL) and we synthesized a chimeric peptide comprised of an anti-bacterial pep tide (KLAKLAK)2 in a D-amino acid configuration coupled to SMSIARL. We have shown in other work that, when targeted to tumor angiogenesis, the proapoptotic peptide triggers apoptosis in the angiogenic endothelial cells in tumor vasculature suppressing tumor growth (Ellerby et al., 1999). The prostate-targeted proapoptotic peptide chimera has a similar effect in the prostate. We are continuing this work by attempting to show that reducing the size of the prostate can reduce or delay the incidence of prostate cancer in the prostate-cancer prone transgenic TRAMP mice. In sum, we have discovered an effective prostate-homing pep tide. It is specific for the prostate vasculature, and it can direct a therapeutic compound (a proapoptotic peptide) into the prostate and effect the organ's shrinkage
Immunoadsorbents in protein purification( Book )

2 editions published in 1976 in English and held by 1 WorldCat member library worldwide

Cell-to-cell contact and extracellular matrix( Book )

1 edition published in 1997 in English and held by 1 WorldCat member library worldwide

Vascular zip codes in targeted delivery of multifunctional nanodevices by Erkki Ruoslahti( Visual )

1 edition published in 2009 in English and held by 1 WorldCat member library worldwide

(CIT): This laboratory screens phage libraries in live mice to identify peptides that direct phage homing to a specific target in the body. When the libraries are injected into the circulation, tissue-specific or tumor-specific differences in endothelial cells are primarily targeted. We have identified tumor-homing peptides that recognize angiogenesis-associated or tumor-type specific markers in tumor blood vessels, or distinguish the vessels of pre-malignant lesions from those of the corresponding normal tissues and of fully malignant tumors. Homing peptides have also revealed a zip code system of molecular changes in tumor lymphatics. We have used synthetic homing peptides identified by phage display to target nanoparticles to tumors. The vasculature is an excellent target because blood supply is important for tumor growth and because tumor vessels are readily available for circulating particles. The homing peptides deliver nanoparticles into tumors in a highly selective manner, and we have developed a nanoparticle that amplifies its own homing to tumors. Quite recently, we have discovered peptides that specifically home to tumor vessels, extravasate, enter into cells, and spread within tumor tissue. These tumor-penetrating peptides are capable of taking a payload, such as nanoparticles, deep into tumor tissue. We have elucidated the molecular pathway for the cell and tissue penetration by these peptides. We are using these peptides to construct multifunctional, targeted nanoparticles that also serve as tumor imaging probes and drug carriers
Jak rozsiewa się rak? by Erkki Ruoslahti( )

1 edition published in 1996 in Polish and held by 1 WorldCat member library worldwide

Methods in enzymology. - 245: Extracellular matrix components( Book )

1 edition published in 1994 in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.63 (from 0.56 for Fibroblast ... to 0.99 for Targeting ...)

Extracellular matrix components Methods in enzymology Methods in enzymology. - 245: Extracellular matrix components
Covers
Methods in enzymologyMethods in enzymology. - 245: Extracellular matrix components
Alternative Names
Erkki Ruoslahti Amerikaans arts

Erkki Ruoslahti finnisch-US-amerikanischer Zellbiologe und Krebsforscher

Ruoslahti, Erkki

エルキ・ルースラーティ

艾爾基·羅斯拉堤

Languages